Engineered ACE2 decoy in dry powder form for inhalation: A novel therapy for SARS-CoV-2 variants.

ABSTRACT: The persistent threat of SARS-CoV-2 and the emergence of new variants has prompted the development of a novel, easily administered modality that can overcome viral mutations. The engineered ACE2 decoy shows neutralizing activity comparable to monoclonal antibodies and is broadly effective against SARS-CoV-2 variants and ACE2-utilizing sarbecoviruses. In addition to intravenous administration, this decoy has shown antiviral efficacy through nebulized aerosol inhalation in murine and primate models, offering a dose-sparing advantage. Clinically, dry powder formulation is ideal for convenience and storage but poses challenges for protein biologics. This study developed a freeze-dried spray formulation of the ACE2 decoy for inhalation. The trehalose and leucine-based excipient maintained neutr

SUBMITTER: Ito T 

PROVIDER: S-EPMC12019485 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature